Can't give you an exact but they will price the drug low enough to get into formularies easily. Take a look at numbers from the recent market assessment if you haven't already.
Also, and this is a key fact imo, they were offered a buy out totaling 48 million back in 2012 that they turned. This was before great phase 3 results and all the patent protection.
News 
Market Data 
Discover 
